Glen Eagle Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34K | Sell |
425
-108
| -20% | -$8.9K | ﹤0.01% | 498 |
|
|
2025
Q4 | $45.4K | Sell |
533
-70
| -12% | -$5.75K | 0.01% | 464 |
|
|
2025
Q3 | $46.9K | Sell |
603
-353
| -37% | -$27.6K | 0.01% | 466 |
|
|
2025
Q2 | $74.8K | Sell |
956
-1,138
| -54% | -$84.9K | 0.01% | 359 |
|
|
2025
Q1 | $152K | Sell |
2,094
-6,597
| -76% | -$472K | 0.03% | 270 |
|
|
2024
Q4 | $643K | Sell |
8,691
-4,678
| -35% | -$327K | 0.11% | 120 |
|
|
2024
Q3 | $882K | Sell |
13,369
-1,056
| -7% | -$76.7K | 0.15% | 107 |
|
|
2024
Q2 | $1.33M | Buy |
14,425
+4,965
| +52% | +$440K | 0.24% | 76 |
|
|
2024
Q1 | $904K | Buy |
9,460
+7,395
| +358% | +$621K | 0.17% | 100 |
|
|
2023
Q4 | $157K | Buy |
2,065
+1,398
| +210% | +$97.3K | 0.03% | 250 |
|
|
2023
Q3 | $46.2K | Hold |
667
| – | – | 0.01% | 389 |
|
|
2023
Q2 | $62.9K | Hold |
667
| – | – | 0.01% | 349 |
|
|
2023
Q1 | $55.2K | Hold |
667
| – | – | 0.01% | 353 |
|
|
2022
Q4 | $49.8K | Hold |
667
| – | – | 0.01% | 361 |
|
|
2022
Q3 | $55.1K | Hold |
667
| – | – | 0.02% | 338 |
|
|
2022
Q2 | $63.4K | Hold |
667
| – | – | 0.02% | 335 |
|
|
2022
Q1 | $78.5K | Hold |
667
| – | – | 0.02% | 315 |
|
|
2021
Q4 | $86.4K | Hold |
667
| – | – | 0.02% | 300 |
|
|
2021
Q3 | $75.5K | Sell |
667
-23
| -3% | -$2.63K | 0.02% | 311 |
|
|
2021
Q2 | $71.5K | Hold |
690
| – | – | 0.02% | 315 |
|
|
2021
Q1 | $57.7K | Hold |
690
| – | – | 0.02% | 323 |
|
|
2020
Q4 | $62.9K | Sell |
690
-75
| -10% | -$6.22K | 0.02% | 294 |
|
|
2020
Q3 | $61.1K | Sell |
765
-3
| -0.4% | -$234 | 0.03% | 278 |
|
|
2020
Q2 | $53.1K | Buy |
768
+78
| +11% | +$5.54K | 0.03% | 275 |
|
|
2020
Q1 | $43.4K | Sell |
690
-99
| -13% | -$7.14K | 0.03% | 278 |
|
|
2019
Q4 | $61.4K | Buy |
789
+3
| +0.4% | +$234 | 0.03% | 290 |
|
|
2019
Q3 | $57.6K | Buy |
786
+96
| +14% | +$6.74K | 0.04% | 268 |
|
|
2019
Q2 | $42.5K | Hold |
690
| – | – | 0.03% | 295 |
|
|
2019
Q1 | $44K | Hold |
690
| – | – | 0.03% | 278 |
|
|
2018
Q4 | $35.2K | Sell |
690
-75
| -10% | -$3.79K | 0.03% | 280 |
|
|
2018
Q3 | $44.4K | Sell |
765
-12
| -2% | -$587 | 0.03% | 271 |
|
|
2018
Q2 | $37.7K | Sell |
777
-3
| -0.4% | -$140 | 0.03% | 285 |
|
|
2018
Q1 | $36.3K | Buy |
780
+723
| +1,268% | +$31.4K | 0.03% | 281 |
|
|
2017
Q4 | $2.14K | Sell |
57
-1,314
| -96% | -$48.2K | ﹤0.01% | 565 |
|
|
2017
Q3 | $50K | Buy |
1,371
+771
| +129% | +$29.4K | 0.05% | 237 |
|
|
2017
Q2 | $23.6K | Buy |
600
+75
| +14% | +$2.74K | 0.02% | 290 |
|
|
2017
Q1 | $16.5K | Buy |
525
+150
| +40% | +$4.7K | 0.01% | 311 |
|
|
2016
Q4 | $11.7K | Buy |
+375
| New | +$12.2K | 0.01% | 334 |
|
Other funds holding EW
VCM
VPM
Glen Eagle Advisors's EW Position: Q1 2026 in Review
Glen Eagle Advisors reduced its Edwards Lifesciences (EW) stake by 20% in Q1 2026, selling an estimated $8.9K and leaving 425 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #498.
Glen Eagle Advisors first reported a position in EW in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.33M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Glen Eagle Advisors held 425 shares of Edwards Lifesciences worth $34K as of Q1 2026.
- Glen Eagle Advisors sold 108 Edwards Lifesciences shares in Q1 2026, an estimated $8.9K.
- Edwards Lifesciences made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #498 holding.
- Glen Eagle Advisors first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Edwards Lifesciences position peaked at $1.33M in Q2 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.